Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results